Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 7/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19451109 | 0.91 | PARP14 (0.56) | L3MBTL1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL14728026 | 0.87 | CETP (0.64) | L3MBTL1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL6689158 | 0.83 | ALDH1A1 (0.74) | ALDH1A1HPGDHTTSMN1; SMN2MAPK1 | |
| SCHEMBL943096 | 0.81 | PDK1 (0.71) | L3MBTL1ALDH1A1HPGDHTTJAK2 | |
| SCHEMBL11599081 | 0.81 | L3MBTL1 (0.64) | L3MBTL1ALDH1A1SMN1; SMN2MAPK1MAPT | |
| SCHEMBL914296 | 0.81 | PDK1 (0.70) | ALDH1A1HPGDHTTSMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL28203570 | 0.79 | PDK1 (0.68) | ALDH1A1HPGDHTTSMN1; SMN2MAPK1 | |
| SCHEMBL18158146 | 0.79 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL11599074 | 0.79 | L3MBTL1 (0.66) | L3MBTL1ALDH1A1SMN1; SMN2MAPTCYP2C19 | |
| SCHEMBL7299817 | 0.78 | GAA (0.56) | ALDH1A1HTTJAK2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2121612-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | L3MBTL1 4420/4885ALDH1A1 3405/4885HPGD 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.